Conroe, Texas — According to state and local economic development sources VGXI plans to invest $31,000,000.00 to build out 19,907 square feet of new space in Conroe. The company plans to occupy the new space at 10130 Deison Park Boulevard in Conroe, on or about March 1, 2023. According to the company website VGXI is a contract manufacturing organization that produces DNA plasmids under GMP for human clinical trials. With nearly 20 years experience manufacturing biopharmaceuticals, VGXI has produced over 175 batches of clinical grade DNA for trials in the U.S., Canada, Europe, Asia, and Australia. The Companys patented AIRMIX lysis technology enables high purity, highly concentrated plasmid formulations from 1 to 15 mg/ml allowing customers to prepare low volume and multi-plasmid formulations. Its world-class process development scientists and purpose-built GMP production facility combine to ensure the success of challenging clinical programs.

To learn more about VGXI, visit http://vgxii.com/

Company Contact:
Young Park, Chief Executive Officer
281-296-7300

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved